Breaking News Instant updates and real-time market news.

ALKS

Alkermes

$59.29

4.6 (8.41%)

, BMY

Bristol-Myers

$65.35

1.48 (2.32%)

05:15
02/15/18
02/15
05:15
02/15/18
05:15

Alkermes catalysts are the major focus this year, says Citi

Citi analyst Liav Abraham says that while Alkermes' (ALKS) fiscal 2018 revenue outlook came in below expectations, catalysts are the "major force this year." The analyst expects data from two of the company's pivotal programs and clarity around the regulatory pathway for ALKS 5461. Further, the strategic value of ALKS 4230 "can also not be discounted," following the collaboration between Bristol-Myers (BMY) and Nektar Therapeutics (NKTR), Abraham tells investors in a post-earnings research note. ALKS 4230, an IL-2 inhibitor, gives Alkermes optionality as it is not an "obvious" fit into the company's psychiatry-oriented portfolio, the analyst contends. She keeps a Neutral rating on Alkermes with a $62 price target.

ALKS

Alkermes

$59.29

4.6 (8.41%)

BMY

Bristol-Myers

$65.35

1.48 (2.32%)

NKTR

Nektar

$84.00

8.34 (11.02%)

  • 15

    Feb

  • 26

    Feb

  • 05

    Mar

  • 08

    Mar

  • 04

    Apr

  • 03

    May

ALKS Alkermes
$59.29

4.6 (8.41%)

11/27/17
JEFF
11/27/17
NO CHANGE
Target $66
JEFF
Buy
Alkermes made prudent move selling ALKS 8700 rights, says Jefferies
Jefferies analyst Biren Amin thinks Alkermes (ALKS) made a prudent move by selling the rights of ALKS 8700 to Biogen (BIIB). The multiple sclerosis drug did not fit into the company's portfolio, Amin tells investors in an intraday research note. He believes Alkermes can now focus on programs such as ALKS-4230, an IL-2 for oncology. The analyst has a Buy rating on the shares with a $66 price target.
11/28/17
FBCO
11/28/17
NO CHANGE
Target $66
FBCO
Outperform
Alkermes agreement with Biogen should help monetize ALKS 8700, says Credit Suisse
Credit Suisse analyst Vamil Divan views Alkermes (ALKS) ALKS 8700 agreement with Biogen (BIIB) as a positive financial move for an underappreciated pipeline asset. The analyst notes that ALKS 8700 has not been given much credit by investors to date due to limited clinical data and patent uncertainty. Divan reiterates an Outperform rating and $66 price target on Alkermes shares.
11/28/17
BERN
11/28/17
NO CHANGE
Target $318
BERN
Outperform
Biogen price target raised to $318 from $310 at Bernstein
Bernstein analyst Aaron Gal raised his price target for Biogen (BIIB) to $318 from $310 after the company announced a licensing agreement with Alkermes (ALKS) to develop and commercialize ALKS 8700, a modified fumarate with a potentially differentiated GI tolerability profile. The analyst views this important improvement in Biogen's position in MS given the risk of generic Tecfidera. Further, Gal thinks the Street may be underappreciating the value of the asset. He reiterates an Outperform rating on Biogen's shares.
12/14/17
JEFF
12/14/17
NO CHANGE
Target $66
JEFF
Buy
Jefferies received positive feedback on Vivitrol at psychiatry conference
Jefferies analyst Biren Amin says he received positive feedback on Alkermes' Vivitrol at the American Academy of Addiction Psychiatry conference. Key opinion leaders have a consensus view on Vivitrol of its comparable efficacy and safety versus Suboxone, Amin tells investors in a research note. Psychiatrists view the recently approved Sublocade as a meaningful alternative to reduce abusive use of oral Suboxone, but don't believe it as a major threat to Vivitrol as physician acceptance of Vivitrol largely depends on its unique antagonist mechanism, the analyst adds. He believes Alkermes is in a strategic position for "significant growth" of Vivitrol longer term, supported by physician advocacy, patient awareness and Trump administration's pledges to fight the opioid epidemic. Amin has a Buy rating on Alkermes with a $66 price target.
BMY Bristol-Myers
$65.35

1.48 (2.32%)

02/06/18
LEER
02/06/18
NO CHANGE
Target $76
LEER
Outperform
Bristol-Myers price target raised to $76 from $71 at Leerink
Leerink analyst Seamus Fernandez raised his price target for Bristol-Myers to $76 from $71 and increased Opdivo and Yervoy estimates following positive CM-227 PFS Topline. The analyst reiterates an Outperform rating on the shares.
02/14/18
MZHO
02/14/18
NO CHANGE
Target $89
MZHO
Buy
Nektar deal with Bristol-Myers could eventually lead to takeover, says Mizuho
After Nektar (NKTR) announced a new immune-oncology collaboration agreement with Bristol-Myers Squibb (BMY), Mizuho analyst Difei Yang said she believes the deal values Nektar at approximately $9B-$10B and may lead to an eventual takeout. She maintains her Buy rating and $89 price target on Nektar shares.
02/14/18
JEFF
02/14/18
NO CHANGE
Target $88
JEFF
Buy
Nektar takeover not off table with Bristol deal, says Jefferies
Jefferies analyst David Steinberg finds it important that Nektar Therapeutics (NKTR) retains ownership of NKTR-214 following its collaboration with Bristol-Myers (BMY) and that it can continue to collaborate with other companies. Further, the potential to be acquired is not off the table, Steinberg tells investors in a research note. The analyst keeps a Buy rating on Nektar with an $88 price target.
02/15/18
MSCO
02/15/18
UPGRADE
MSCO
Overweight
Bristol-Myers upgraded to Overweight from Equal Weight at Morgan Stanley
NKTR Nektar
$84.00

8.34 (11.02%)

01/22/18
MZHO
01/22/18
NO CHANGE
Target $89
MZHO
Buy
Nektar price target raised to $89 from $45 at Mizuho
Mizuho analyst Difei Yang raised her price target for Nektar Therapeutics to $89 citing the "impressive" safety and efficacy data observed so far in clinical trials for NKTR-214. The drugmaker closed Friday up $1.43 to $71.59. There is a "good chance" the upcoming data readouts at the American Society of Clinical Oncology in June will be positive, which could provide "strong upside for the shares," Yang tells investors in a research note. The analyst believes NKTR-214 has been impressive across all cancer types and is "ahead of the competition." She believes the drug has the potential to work across many indications and points out the asset is wholly-owned by Nektar. From a potential acquirer's perspective, a wholly-owned asset is more attractive, Yang contends. She reiterates a Buy rating on Nektar.
02/05/18
JEFF
02/05/18
NO CHANGE
Target $88
JEFF
Buy
Bristol-Myers makes sense as potential Nektar acquirer, says Jefferies
Jefferies analyst David Steinberg believes Bloomberg's report that Nektar Therapeutics (NKTR) is exploring strategic options is not surprising. For many years Nektar's most important assets were out licensed, but that is no longer the case, Steinberg tells investors in a research note. The company's current partner Bristol-Myers Squibb (BMY) would make sense to be on the short list of potential acquirer, the analyst adds. Steinberg keeps a Buy rating on Nektar with an $88 price target.

TODAY'S FREE FLY STORIES

PVG

Pretium Resources

$7.43

(0.00%)

18:11
12/14/18
12/14
18:11
12/14/18
18:11
Hot Stocks
Pretium Resources: Brucejack approved for production hike to 3,800 tonnes/day »

Pretium Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$15.47

-0.2 (-1.28%)

17:52
12/14/18
12/14
17:52
12/14/18
17:52
Periodicals
FCA says four U.S. plants to have down-time in January, Detroit News says »

Fiat Chrysler said that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNOA

Sonoma Pharmaceuticals

$0.75

-0.0342 (-4.36%)

, CCNI

Command Center

$4.00

-0.075 (-1.84%)

17:43
12/14/18
12/14
17:43
12/14/18
17:43
Hot Stocks
Sonoma Pharmaceuticals CEO Jim Schutz resigns, Frederick Sandford succeeds »

Sonoma Pharmaceuticals…

SNOA

Sonoma Pharmaceuticals

$0.75

-0.0342 (-4.36%)

CCNI

Command Center

$4.00

-0.075 (-1.84%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$62.09

-1.47 (-2.31%)

, XLU

Utilities SPDR

$56.81

-0.13 (-0.23%)

17:38
12/14/18
12/14
17:38
12/14/18
17:38
General news
Week ending ETF scorecard: Energy, Financials lead the decline »

S&P500 SECTORS:…

XLE

Energy Select Sector SPDR

$62.09

-1.47 (-2.31%)

XLU

Utilities SPDR

$56.81

-0.13 (-0.23%)

IYR

DJ US Real Estate Index Fund

$80.37

-0.14 (-0.17%)

XLP

Consumer Staples Sector SPDR

$54.51

-0.97 (-1.75%)

XLY

Consumer Discretionary Sector SPDR

$102.33

-1.75 (-1.68%)

XLB

S&P Select Materials SPDR

$51.37

-0.37 (-0.72%)

XLF

Financial Select Sector

$24.25

-0.24 (-0.98%)

XLV

Health Care Select Sector SPDR

$88.99

-3.05 (-3.31%)

XLK

Technology Select Sector SPDR

$64.58

-1.6 (-2.42%)

XLI

Industrial Select Sector SPDR

$67.06

-0.95 (-1.40%)

GLD

SPDR Gold Shares

$117.10

-0.44 (-0.37%)

SLV

iShares Silver Trust

$13.69

-0.175 (-1.26%)

USO

United States Oil Fund

$10.83

-0.38 (-3.39%)

UNG

United States Natural Gas Fund

$30.78

-2.64 (-7.90%)

HYG

iShares iBoxx $ High Yield Corporate Bond

$83.17

-0.365 (-0.44%)

LQD

iShares iBoxx $ Investment Grade Corporate Bond

$112.72

-0.125 (-0.11%)

TLT

iShares 20+ Year Treasury Bond Fund

$118.47

0.38 (0.32%)

IEF

iShares 7-10 Year Treasury Bond ETF

$102.57

0.19 (0.19%)

SHY

iShares 1-3 Year Treasury Bond

$83.31

0.055 (0.07%)

IWD

iShares Russell 1000 Value

$116.15

-1.71 (-1.45%)

IWF

iShares Russell 1000 Growth

$135.70

-2.96 (-2.13%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EEI

Ecology & Environment

$11.50

0.2 (1.77%)

17:35
12/14/18
12/14
17:35
12/14/18
17:35
Hot Stocks
Ecology & Environment receives Nasdaq noncompliance notice »

On December 13, 2018,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LBC

Luther Burbank

$8.96

-0.045 (-0.50%)

17:34
12/14/18
12/14
17:34
12/14/18
17:34
Hot Stocks
Luther Burbank announces systematic share repurchase plan »

Luther Burbank announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MYND

MYnd Analytics

$1.33

0.01 (0.76%)

17:31
12/14/18
12/14
17:31
12/14/18
17:31
Syndicate
Breaking Syndicate news story on MYnd Analytics »

MYnd Analytics files to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RLGT

Radiant Logistics

$4.76

-0.06 (-1.24%)

17:29
12/14/18
12/14
17:29
12/14/18
17:29
Syndicate
Breaking Syndicate news story on Radiant Logistics »

Radiant Logistics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KALV

KalVista

$22.62

-1.39 (-5.79%)

17:29
12/14/18
12/14
17:29
12/14/18
17:29
Syndicate
Breaking Syndicate news story on KalVista »

KalVista files $200M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$260.61

-4.8 (-1.81%)

17:25
12/14/18
12/14
17:25
12/14/18
17:25
Hot Stocks
POTUS names Mick Mulvaney acting WH chief of staff »

U.S. President Donald…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$260.61

-4.8 (-1.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTN

Raytheon

$169.87

-2.585 (-1.50%)

17:20
12/14/18
12/14
17:20
12/14/18
17:20
Hot Stocks
Raytheon awarded $149.44M Navy contract for Standard Missile-2 Block IIIC »

Raytheon has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EOG

EOG Resources

$100.08

-2.73 (-2.66%)

17:15
12/14/18
12/14
17:15
12/14/18
17:15
Syndicate
Breaking Syndicate news story on EOG Resources »

EOG Resources files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNCB

First National Community Bancorp, Inc.

$9.35

0.04 (0.43%)

17:14
12/14/18
12/14
17:14
12/14/18
17:14
Hot Stocks
First National Community Bancorp names R. Gregory Collins as new EVP »

FNCB Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXT

Textron

$49.49

-0.48 (-0.96%)

17:14
12/14/18
12/14
17:14
12/14/18
17:14
Hot Stocks
Textron awarded $314.29M Navy contract modification for LLTM procurement »

Textron has been awarded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FLDM

Fluidigm

$7.79

-0.39 (-4.77%)

17:14
12/14/18
12/14
17:14
12/14/18
17:14
Hot Stocks
Breaking Hot Stocks news story on Fluidigm »

Levin Capital lowers…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

WTFC

Wintrust Financial

$67.41

-0.88 (-1.29%)

17:06
12/14/18
12/14
17:06
12/14/18
17:06
Hot Stocks
Wintrust Financial acquires Elektra Holding in roughly $51.9M deal »

Wintrust Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMC

AMC Entertainment

$14.51

-0.35 (-2.36%)

17:04
12/14/18
12/14
17:04
12/14/18
17:04
Syndicate
Breaking Syndicate news story on AMC Entertainment »

AMC Entertainment files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EFX

Equifax

$97.19

0.07 (0.07%)

17:03
12/14/18
12/14
17:03
12/14/18
17:03
Hot Stocks
Equifax Canada acquires JLR Inc. »

Equifax Canada announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 18

    Dec

DFS

Discover

$61.83

-1.41 (-2.23%)

17:03
12/14/18
12/14
17:03
12/14/18
17:03
Hot Stocks
Discover executive chairman Nelms to step down effective December 31 »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AUTO

AutoWeb

$2.34

-0.01 (-0.43%)

17:00
12/14/18
12/14
17:00
12/14/18
17:00
Hot Stocks
Daniel M. Negari reports 7.1% stake in AutoWeb »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNI

Canadian National

$77.33

-1.39 (-1.77%)

16:46
12/14/18
12/14
16:46
12/14/18
16:46
Hot Stocks
Canadian National, Unifor Local 100 reach tentative agreement »

CN announced that a new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CSCO

Cisco

$45.80

-1.66 (-3.50%)

16:44
12/14/18
12/14
16:44
12/14/18
16:44
Recommendations
Cisco analyst commentary  »

Tigress Financial sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 10

    Jan

  • 04

    Mar

TEL

TE Connectivity

$73.01

-0.59 (-0.80%)

16:44
12/14/18
12/14
16:44
12/14/18
16:44
Hot Stocks
TE Connectivity raises quarterly dividend to 46c from 44c per share »

TE Connectivity board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEL

TE Connectivity

$73.01

-0.59 (-0.80%)

16:42
12/14/18
12/14
16:42
12/14/18
16:42
Hot Stocks
TE Connectivity board approves $1.5B share repurchase authorization »

TE Connectivity announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRQS

Borqs Technologies

$3.85

0.1 (2.67%)

16:36
12/14/18
12/14
16:36
12/14/18
16:36
Hot Stocks
Breaking Hot Stocks news story on Borqs Technologies »

Borqs Technologies files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.